{"id":378,"date":"2019-07-31T09:44:29","date_gmt":"2019-07-31T09:44:29","guid":{"rendered":"http:\/\/events.marketsandmarkets.com\/blog\/?p=378"},"modified":"2019-07-31T09:44:29","modified_gmt":"2019-07-31T09:44:29","slug":"speaker-interview-with-stefan-glueck-for-2nd-annual-marketsandmarkets-next-gen-immuno-oncology-congress","status":"publish","type":"post","link":"https:\/\/events.marketsandmarkets.com\/blognew\/speaker-interview-with-stefan-glueck-for-2nd-annual-marketsandmarkets-next-gen-immuno-oncology-congress\/","title":{"rendered":"Speaker Interview With Stefan Glueck For 2ND Annual MarketsandMarkets Next Gen Immuno-Oncology Congress"},"content":{"rendered":"\n<p><strong><br>Philadelphia, USA July 31, 2019<\/strong>&nbsp;\u2013 MarketsandMarkets recently interviewed&nbsp;<strong>Stefan Glueck<\/strong>, Senior Vice President, Global Medical Affairs, <strong>Celgene<\/strong> regarding the&nbsp;<strong>2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress<\/strong>, taking place on September 19 \u2013 20, 2019 at&nbsp;<strong>Hilton Garden Inn Philadelphia Center City.<\/strong><\/p>\n\n\n\n<p><strong>Q<\/strong>. What are the recent advances in the immune-oncology and current challenges that need immediate attention? <\/p>\n\n\n\n<p><strong>A.<\/strong> advances: more indication using ICI and combinations with chemo, and other IO. even brain metastases seem to respond to smart combinations. challenges: primary and secondary resistance and still less than 50% of patients even in effective areas are responding<\/p>\n\n\n\n<p><strong>Q<\/strong>. What are the new opportunities emerging in your field of work?<\/p>\n\n\n\n<p><em>1. new indications (e.g. BrCa ) and lines of therapy e.g. earlier stages.<\/em><br><em>2. established chemotherapy combinations plus ICI and other IO<\/em><\/p>\n\n\n\n<p><strong>Q<\/strong>. What are the key take away points from your presentation topic which will help in building the knowledge base of attendees? <\/p>\n\n\n\n<p><strong>A.<\/strong>  Chemotherapy should be one of the MOA to increase efficacy and make otherwise less responsive tumours sensitive to ICI. new indications should be explored  <\/p>\n\n\n\n<p>Q. Hope you had a chance to go through the agenda, what are your views on it and how helpful it is to the targeted audience?  <\/p>\n\n\n\n<p><strong>A.<\/strong>  all is actually well designed <\/p>\n\n\n\n<ul class=\"is-layout-flex wp-block-gallery-1 wp-block-gallery columns-1 is-cropped\"><li class=\"blocks-gallery-item\"><figure><img loading=\"lazy\" width=\"600\" height=\"170\" src=\"http:\/\/events.marketsandmarkets.com\/blog\/wp-content\/uploads\/2019\/07\/2nd-NGIO_USA_Banner_600x170.jpg\" alt=\"\" data-id=\"375\" data-link=\"http:\/\/events.marketsandmarkets.com\/blog\/speaker-interview-with-frank-borriello-for-2nd-annual-marketsandmarkets-next-gen-immuno-oncology-congress\/2nd-ngio_usa_banner_600x170\/\" class=\"wp-image-375\" srcset=\"https:\/\/events.marketsandmarkets.com\/blognew\/wp-content\/uploads\/2019\/07\/2nd-NGIO_USA_Banner_600x170.jpg 600w, https:\/\/events.marketsandmarkets.com\/blognew\/wp-content\/uploads\/2019\/07\/2nd-NGIO_USA_Banner_600x170-200x57.jpg 200w\" sizes=\"(max-width: 600px) 100vw, 600px\" \/><\/figure><\/li><\/ul>\n\n\n\n<p><strong>Stefan Glueck<\/strong> will present his insights on &#8220;Update on ICI data in early and metastatic breast cancer&#8221;<\/p>\n\n\n\n<p style=\"text-align:left\">The latest conference agenda and complete speaker line-up is available to download on the conference page, where you can also register \u2013&nbsp;<a href=\"https:\/\/bit.ly\/2LNkgpQ\" target=\"_blank\" rel=\"noopener\">https:\/\/bit.ly\/2LNkgpQ<\/a><\/p>\n\n\n\n<p>For more inquiries contact&nbsp;<strong>Amit Shelke<\/strong>, Marketing Manager on&nbsp;<a href=\"mailto:amit.shelke@marketsandmarkets.com\"><strong>amit.shelke@marketsandmarkets.com<\/strong><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Philadelphia, USA July 31, 2019&nbsp;\u2013 MarketsandMarkets recently interviewed&nbsp;Stefan Glueck, Senior Vice President, Global Medical Affairs, Celgene regarding the&nbsp;2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress, taking place on September 19 \u2013 20, 2019 at&nbsp;Hilton Garden Inn Philadelphia Center City. Q. What are the recent advances in the immune-oncology and current challenges that need immediate attention? A. [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":379,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_mi_skip_tracking":false},"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/posts\/378"}],"collection":[{"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/comments?post=378"}],"version-history":[{"count":1,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/posts\/378\/revisions"}],"predecessor-version":[{"id":380,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/posts\/378\/revisions\/380"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/media\/379"}],"wp:attachment":[{"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/media?parent=378"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/categories?post=378"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/tags?post=378"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}